Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini Institute.

ABSTRACT:

Background

The Ramazzini Institute (RI) has completed nearly 400 cancer bioassays on > 200 compounds. The European Food Safety Authority (EFSA) and others have suggested that study design and protocol differences between the RI and other laboratories by may contribute to controversy regarding cancer hazard findings, principally findings on lymphoma/leukemia diagnoses.

Objective

We aimed to evaluate RI study design, protocol differences, and accuracy of tumor diagnoses for their impact on carcinogenic hazard characterization.

Methods

We analyzed the findings from a recent Pathology Working Group (PWG) review of RI procedures and tumor diagnoses, evaluated consistency of RI and other laboratory findings for chemicals identified by the RI as positive for lymphoma/leukemi

SUBMITTER: Gift JS 

PROVIDER: S-EPMC3852791 | biostudies-literature | 2013 Nov-Dec

REPOSITORIES: biostudies-literature